 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | DNA Genotek |
| Street 1: | 2 Beaverbrook Rd |
| Street 2: | |
| City: | Ottawa |
| Province: | Ontario |
| Post Code: | K2K 1L1 |
| Country: | Canada |
| Phone: | 613.723.5757 |
| Organization Email: | geoffrey.graham@dnagenotek.com |
| Web Site: | http://www.dnagenotek.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| DNA Genotek, based in Ottawa, Canada, is a leader in the development and commercialization of biospecimen collection and stabilization technologies with over 4,000 customers worldwide in over 100 countries. Our devices and chemistries improve patient access by enabling safe and simple specimen collection using technologies that are stable long-term at ambient temperatures. Our core values are to provide affordable solutions to improve sample quality, enable more tests and ensure high quality results to impact patient care and global health outcomes. In support of the global fight to end TB, DNA Genotek has developed two technologies that address some of the main challenges high burden, developing countries face in their daily battle to improve patient access to TB diagnostics and increase case detection rates. We have developed these technologies with the end-users in mind and an understanding of the daily constraints laboratories face when testing sputum samples in a large-scale national program. Our technologies provide solutions to three significant challenges: 1) Improve sputum sample quality to enable ambient temperature transport 2) Simplify laboratory workflows to ensure worker safety, reduce costs and increase throughput 3) Improve TB DNA yield to provide a positive impact on molecular test sensitivities Our technologies have been specifically designed to integrate seamlessly into existing testing algorithms. They are compatible with all gold-standard tests including smear microscopy, solid and liquid (MGIT) culture, Cepheid GeneXpert MTB/RIF, Hain Life Sciences Line Probe Assay, DNA-based PCR tests, and sequencing technologies for molecular drug susceptibility testing. DNA Genotek is committed to improving global health and joining in the fight to end the TB epidemic by 2035. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities |
Other Organization Information | |
| Total number of staff in your organization: | 51 - 99 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We are working with Canadian laboratories and partners to develop better transportation methods to enable improved access to care for remote populations. | |
Geographical Reach | |
| Which country is your headquarters located in: | Canada |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Botswana Cambodia Cameroon Canada Central African Republic Denmark Eswatini Ghana India Italy Kenya Kyrgyzstan Lesotho Mozambique Myanmar Nepal Nigeria Pakistan Peru Philippines Republic of Moldova Rwanda South Africa Uganda United States of America Zambia Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Provide tools to enable more patients to be rapidly tested for DR-TB. Improve molecular detection assays by providing tools to increase the amount of DNA recovered from a sputum sample. Make direct sequencing from sputum samples a reality. Laboratory Strengthening: Provide cost-effective tools to laboratories to increase throughput for sample processing, decrease contamination rates and improve test-to-results times. New Diagnostics: Support new diagnostics by providing diagnostic-agnostic sample prep solutions to enable the implementation of multiple diagnostic tools without needing to customize sample preperation protocols or transport requirements. New TB Drugs: Provide tools to enable larger cohort studies looking at the efficacy of new TB drugs. New TB Vaccines: Provide tools to enable larger cohort studies looking at the efficacy of new TB vaccines. Research: Decrease system costs and cost-to-patients by providing tools that solve critical problems including sample quality, transport challenges, cost-reductions to laboratories, improved sensitivity for molecular diagnostics and reduced time-to-results for quicker and appropriate treatment of patients. |
|
Declaration | |
| Declaration of interests: No apparent conflicts of interest | |
| Application date: | March 23, 2015 |
| Last updated: | May 25, 2018 |